I can't share your optimism about the FDA. Moxduo has some complex issues and the abuse component is a serious hurdle, it's going to be an uphill battle.
If we are to believe QRX and lets make this clear as I previously said, John Holaday basically said in the conference call they have been mislead by the FDA as they were led to believe they were on track, but the FDA held their true position. If that is the case how are we suppose to trust the FDA going forward? It will be interesting to see what the FDA reports on May 25.
QRX Price at posting:
10.5¢ Sentiment: None Disclosure: Held
